Other languages Mabpharm Limited

Equities

2181

KYG5780F1046

Market Closed - Hong Kong S.E. Other stock markets 09:09:00 03/05/2024 BST			5-day change	1st Jan Change
0.395 ^HKD	0.00%		-4.82%	-14.13%

03-26	Mabpharm Limited Reports Earnings Results for the Full Year Ended December 31, 2023	CI
01-10	Livzon Pharma Recognizes Credit, Asset Impairments	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Mabpharm Limited Reports Earnings Results for the Full Year Ended December 31, 2023	03-26
Livzon Pharma Recognizes Credit, Asset Impairments	01-10
Chinese Drug Regulator Includes Livzon Pharmaceutical Unit's SARS-COV-2 Vaccine for Emergency Use	12-04
Mabpharm Limited Announces Director Changes	11-28
Mabpharm Limited Reports Earnings Results for the Half Year Ended June 30, 2023	25/08/23
China Grants Nod to Livzon Pharmaceutical Subsidiary's Clinical Trials for SARS-CoV-2 Booster Shot	17/07/23
Livzon Pharma Raises Cap in Extended Purchase Agreement to 39 Million Yuan	03/07/23
Mabpharm Limited Reports Earnings Results for the Full Year Ended December 31, 2022	24/03/23
Mabpharm Limited Announces New Drug Application of CMAB009	14/03/23
Livzon Pharma's COVID vaccine gets approval as booster in China	02/09/22
Mabpharm Limited Reports Earnings Results for the Half Year Ended June 30, 2022	26/08/22
Mabpharm Limited Approves the Clinical Trial Application of CMAB015 for the Treatment of Psoriasis and Ankylosing Spondylitis	27/07/22
Mabpharm Limited Announces Approval by National Medical Products Administration of China for the Clinical Trial Application of Biological Class I New Drug Cmab017	05/07/22
Mabpharm Limited Reports Earnings Results for the Full Year Ended December 31, 2021	25/03/22
Livzon Pharma Discloses Phase III Trial Results of SARS-COV-2 Booster; Hong Kong Shares Rise 3%	17/02/22
Mabpharm Limited Announces Approval of Clinical Trial Application of CMAB807X by the National Medical Products Administration of China	13/01/22
Mabpharm : Says New Drug Application in China for Asthma Medication Accepted by Regulator	18/10/21
Livzon Pharmaceutical : Pharma's Assisted Reproductive Drug Wins Clinical Trial Approval in China	13/09/21
Mabpharm Limited Reports Unaudited Consolidated Earnings Results for the Six Months Ended June 30, 2021	27/08/21
Sorrento Therapeutics' : Partner Secures China's Marketing Approval For Infliximab Biobetter	20/07/21

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Mabpharm Limited

Equities

2181

KYG5780F1046

Other languages

Filters